Core Viewpoint - Shanghai Boxun Medical Biological Instrument Co., Ltd. has released its Q3 2025 financial report, showing stable growth in revenue and net profit, while also highlighting significant changes in cash flow and asset management [3]. Financial Data Summary Key Financial Metrics - Total assets increased to CNY 255.04 million, up 1.27% from the previous year [5]. - Net assets attributable to shareholders rose to CNY 200.04 million, reflecting a 3.29% increase [5]. - The asset-liability ratio decreased to 20.70% for the parent company and 21.57% for the consolidated entity [5]. Revenue and Profitability - Year-to-date revenue reached CNY 84.58 million, a slight increase of 0.43% compared to the same period last year [5]. - Net profit attributable to shareholders was CNY 8.54 million, up 4.50% year-on-year [5]. - Basic earnings per share improved to CNY 0.20, a 5.26% increase [5]. Quarterly Performance - Q3 2025 revenue was CNY 32.06 million, representing a 12.81% increase from Q3 2024 [5]. - Net profit for Q3 2025 was CNY 4.91 million, up 14.39% year-on-year [5]. - Cash flow from operating activities showed a significant improvement, with a net outflow of CNY 3.52 million, a 54.78% reduction in outflow compared to the previous year [5]. Significant Changes in Financial Data Cash Management - Cash and cash equivalents decreased by 44.89% to CNY 42.13 million, primarily due to the use of idle funds for cash management [7]. - Accounts receivable increased by 581.24% to CNY 24.05 million, attributed to the timing of payments from distributors [7]. Other Financial Changes - Other current assets increased by 469.79% to CNY 20.60 million, reflecting investments in short-term bank deposits [7]. - Deferred income rose by 54.89% to CNY 1.89 million, due to government subsidies received for R&D projects [8]. Shareholder Structure - The total number of shares outstanding remained at 43.33 million, with major shareholders holding significant stakes [11]. - The largest shareholder, Lv Mingjie, holds 60.33% of the shares, with no changes in ownership during the reporting period [11]. Related Party Transactions - The company engaged in minor related party transactions, including sales to affiliated entities, which did not require board approval due to their small scale [16][17].
发展平稳：博迅生物发布Q3财报